特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
358351

胃抑制ポリペプチド受容体 (GIPR):パイプライン分析

Gastric Inhibitory Polypeptide Receptor - Pipeline Review, H2 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 56 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
胃抑制ポリペプチド受容体 (GIPR):パイプライン分析
出版日: 2020年10月30日
発行: Global Markets Direct
ページ情報: 英文 56 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、胃抑制ポリペプチド受容体 (GIPR) を標的とする薬剤の開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報、最近のニュースや発表などを提供しています。

イントロダクション

  • 調査範囲

胃抑制ポリペプチド受容体 (GIPR) の概要

治療薬の開発

  • 胃抑制ポリペプチド受容体 (GIPR):開発中の製品 - 開発段階別
  • 胃抑制ポリペプチド受容体 (GIPR):開発中の製品 - 治療範囲別
  • 胃抑制ポリペプチド受容体 (GIPR) 開発中の製品 - 適応症別

胃抑制ポリペプチド受容体 (GIPR):パイプライン製品の概況

  • 後期段階の製品
  • 初期段階の製品

胃抑制ポリペプチド受容体 (GIPR):企業で開発中の製品

胃抑制ポリペプチド受容体 (GIPR):大学/機関で開発中の製品

胃抑制ポリペプチド受容体 (GIPR):治療薬の評価

単剤療法/併用療法製品の評価

  • 作用機序別
  • 投与経路別
  • 分子タイプ別

胃抑制ポリペプチド受容体 (GIPR) の治療薬開発に従事している企業

  • Alchemia Limited
  • AstraZeneca Plc
  • Carmot Therapeutics, Inc.
  • Diabetica Limited
  • Longevity Biotech, Inc
  • Novo Nordisk A/S
  • Sanofi
  • Zealand Pharma A/S

胃抑制ポリペプチド受容体 (GIPR) の薬剤プロファイル

胃抑制ポリペプチド受容体 (GIPR):休止中のプロジェクト

胃抑制ポリペプチド受容体 (GIPR):開発が中止された製品

胃抑制ポリペプチド受容体 (GIPR):主なニュースとプレスリリース

付録

図表

List of Tables

List of Tables

  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Indication, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Number of Products under Investigation by Universities/Institutes, H2 2020
  • Products under Investigation by Universities/Institutes, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Pipeline by Amgen Inc, H2 2020
  • Pipeline by Antag Therapeutics ApS, H2 2020
  • Pipeline by Bainan Biotech ApS, H2 2020
  • Pipeline by Carmot Therapeutics Inc, H2 2020
  • Pipeline by Eli Lilly and Co, H2 2020
  • Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2020
  • Pipeline by Kariya Pharmaceuticals IVS, H2 2020
  • Pipeline by Longevity Biotech Inc, H2 2020
  • Pipeline by Zealand Pharma AS, H2 2020
  • Dormant Products, H2 2020
  • Dormant Products, H2 2020 (Contd..1), H2 2020
  • Discontinued Products, H2 2020

List of Figures

List of Figures

  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Top 10 Indications, H2 2020
  • Number of Products by Mechanism of Actions, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020
目次
Product Code: GMDHC2659TDB

Summary:

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) pipeline Target constitutes close to 15 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Gastric Inhibitory Polypeptide Receptor - Pipeline Review, H2 2020, outlays comprehensive information on the Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Glucose-dependent insulinotropic polypeptide receptor (GIPR) is a transmembrane protein in humans which is encoded by the GIPR gene. GIPR is expressed on pancreatic beta-cells which lead to activation and release of insulin. The transcription of this protein is positively controlled by glucose molecules. GIPR is expressed in higher levels when glucose is in higher concentration. The ligand which binds to GIPR is glucose-dependent insulinotropic polypeptide (GIP) also known as gastric inhibitory polypeptide. Glucose-dependent insulinotropic polypeptide is released from the duodenum and small intestine. GIP binds to GIPR though hydrophobic interactions and triggering activation of G protein-coupled receptors, which in turn causes an enzymatic cascade resulting in the increased secretion of insulin. Endogeonous ligands for the receptor include oleylethanolamide and lysophosphatidylcholine. The cause of type 2 diabetes is due to the inability of GIP to bind properly to GIPR.

The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 4, 4, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Central Nervous System, Gastrointestinal, Cardiovascular and Musculoskeletal Disorders which include indications Obesity, Type 2 Diabetes, Alzheimer's Disease, Non-Alcoholic Steatohepatitis (NASH), Diabetes, Non Alcoholic Fatty Liver Disease (NAFLD), Parkinson's Disease, Cardiovascular Risk Factors, Circadian Rhythm Sleep Disorders, Osteoporosis, Primary Biliary Cholangitis (Primary Biliary Cirrhosis) and Primary Sclerosing Cholangitis.

Furthermore, this report also reviews key players involved in Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR)
  • The report reviews Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Overview
  • Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Companies Involved in Therapeutics Development
  • Amgen Inc
  • Antag Therapeutics ApS
  • Bainan Biotech ApS
  • Carmot Therapeutics Inc
  • Eli Lilly and Co
  • Hanmi Pharmaceuticals Co Ltd
  • Kariya Pharmaceuticals IVS
  • Longevity Biotech Inc
  • Zealand Pharma AS
  • Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Drug Profiles
  • AMG-133 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Biologic to Agonize GLP-1R, GIPR and GLR for Diabetes - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CT-868 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • DAJC-1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drugs to Agonize GIP and GLP-2 for Osteoporosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HM-15211 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KP-405 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LBT-6030 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Peptides to Antagonize GIPR for Obesity - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Agonize GIPR and GLP1R for Type 2 Diabetes - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Synthetic Peptide 1 for Type 2 Diabetes, Obesity and Alzheimer's Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Synthetic Peptide 1 to Agonize GIPR for Alzheimer's Disease and Type 1 Diabetes - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Synthetic Peptide to Agonize GIPR and GLP1R for Diabetes - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Synthetic Peptides to Agonize GIP, GR and GLP-1R for Gastrointestinal and Metabolic Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tirzepatide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Dormant Products
  • Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Discontinued Products
  • Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Product Development Milestones
  • Featured News & Press Releases
  • Jun 10, 2020: Lilly begins dosing in cardiovascular outcomes trial of tirzepatide
  • Mar 11, 2020: Hanmi's NASH treatment wins more orphan drug status
  • Feb 28, 2020: Hanmi's anti-NASH drug candidate set to become 'game changer' in global pharmaceutical market
  • Jun 08, 2019: Lilly's tirzepatide demonstrates benefits in data presented at the American Diabetes Associations 79 Scientific Sessions
  • May 29, 2019: Lilly announces webcast to discuss on tirzepatide at the American Diabetes Association's 79th Scientific Sessions
  • Dec 19, 2018: Carmot Therapeutics initiates phase 1 trial to treat type 2 diabetes
  • Oct 05, 2018: Lilly reports positive results for GIP/GLP-1 RA in type 2 diabetes trial
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.